About Zhoumeng Lin
Dr. Zhoumeng Lin is an Associate Professor in the Department of Environmental and Global Health at College of Public Health and Health Professions at the University of Florida. He has joint appointments in Department of Pharmaceutics at College of Pharmacy and Department of Physiological Sciences in College of Veterinary Medicine. He is a member of the Center for Environmental and Human Toxicology (CEHT) and the Center for Pharmacometrics and Systems Pharmacology (CPSP). He received a B.Med. in Preventive Medicine from Southern Medical University in China in 2009 and a Ph.D. in Toxicology from the University of Georgia in 2013. He completed his postdoctoral training in the Institute of Computational Comparative Medicine at Kansas State University in 2016. He was an Assistant Professor from 2016 to 2021 and then an Associate Professor from March to May 2021 at Kansas State University, prior to joining the University of Florida as an Associate Professor in May 2021.
Dr. Lin’s research is focused on the development and application of computational technologies, especially physiologically based pharmacokinetic (PBPK) modeling, machine learning, and artificial intelligence approaches, to study nanomedicine, food safety, nanoparticle and chemical risk assessment. He is a co-author of more than eighty peer-reviewed publications. His publications have received several awards, including the Society of Toxicology Biological Modeling Specialty Section Best Paper Award in 2020 and 2022.
Dr. Lin teaches a graduate level course on PBPK modeling every year. He is a co-editor and a co-author of five chapters of the textbook entitled “Physiologically Based Pharmacokinetic (PBPK) Modeling: Methods and Applications in Toxicology and Risk Assessment”.
Dr. Lin has served as an ad hoc grant reviewer for several agencies, including USDA and NIH. He is an ad hoc member of the Science Advisory Committee on Chemicals (SACC) of US EPA. He has served as an external reviewer on several risk assessment documents on different environmental chemicals for different agencies, including EPA, CDC, and FDA. He has been a member of Society of Toxicology since 2011. He served as a Sunday Host Mentor for the Sunday Undergraduate Education Program organized by the Committee on Diversity Initiatives of Society of Toxicology from 2016 to 2017 and he was a Secretary/Treasurer of Central States Society of Toxicology (CSSOT) from 2018 to 2020. He is now the Vice President of the Biological Modeling Specialty Section (BMSS) and a Councilor of the Nanoscience and Advanced Materials Specialty Section (NAMSS) of Society of Toxicology.
Certified in Public Health (CPH)National Board of Public Health Examiners (NBPHE)
Diplomate of the American Board of Toxicology (DABT)American Board of Toxicology
European Registered Toxicologist (ERT)UK Register of Toxicologists
Population PK/PD Pharmacometrician (Level 1) using Phoenix NLME 8.0 and 8.1Certara Professional Certification
Dr. Lin’s areas of expertise include Toxicology, Risk Assessment, Environmental Health, and Pharmacology. His research interest is in the development and application of computational technologies for environmental chemicals, nanoparticles and drugs in animals and humans to address research questions related to nanomedicine, animal-derived food safety assessment, and environmental chemical risk assessment. The computational technologies used in his research include physiologically based pharmacokinetic (PBPK), pharmacokinetics/pharmacodynamics (PK/PD), toxicogenomics, machine learning, and artificial intelligence (AI) approaches. The long-term goal of his research is to develop AI-assisted computational approaches to support decision-making in human health, animal health, and environmental health (i.e., one health approach).
Currently, there are three specific projects in his laboratory. The first project is to develop PBPK models for drugs in food-producing animals, such as cattle, swine, sheep, goats, chickens, turkeys, and fish. The second project is to develop AI-assisted PBPK models for nanoparticles in both healthy and tumor-bearing animals. The third project is develop PBPK models for environmental chemicals, such as per- and polyfluoroalkyl substances (PFAS) in animals and humans of different life stages.